The recent clearance and a previous clearance together allow the use of Paige's FullFocus digital pathology image viewing software with scanners by Philips, Leica, and Hamamatsu.

The company said it expects Q4 2024 revenues of roughly $34.9 million, up from $31.5 million in Q4 2023 and above the consensus Wall Street estimate of $34.4 million.

NEW YORK – Pathology software developer Aiosyn said recently that it has gained CE marking for an algorithm that is used for mitotic figure counting in breast cancer diagnostics. The Nijmegen, ...

The reagents are meant for measuring aCL and aβ2GP1 antibody levels in human serum to aid the diagnosis of primary and secondary APS.

Following OraSure's November 2024 lawsuit accusing NowDx of misappropriating trade secrets, NowDx has countersued OraSure over similar allegations.

The company received conditional approval from New York state for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays.

Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.

The rapid spinning disk-based immunoassay technology will enhance BioMérieux's offering at the point of care, the firm said.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

The chemiluminescence-based immunoassay is used for the direct quantitative measurement of free testosterone in serum or plasma, with results in 48 minutes.

Tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Clinical Genomics, and the University of Pittsburgh Medical Center will no longer be covered.

Biomy has developed its DeepPathFinder digital pathology platform to analyze images to classify cell and tissue types in specific regions.